Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nebulized HCQ01 for COVID-19
NCT05113810Phase 2Unknown
- Sponsor
- Jordan Ministry of Health
- Start
- Mar 2022
- Primary completion
- Jul 2022
- Modality
- Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of ISPM19 in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Jordan Ministry of Health. Primary endpoint: WHO Ordinal Scale for Clinical Improvement at Day 14. Status: unknown.
02
Drugs
ISPM19
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05113810.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05113810.